Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU 1 Multiple Myeloma 1 Leukemia, Myeloid 1

Interventions

fludarabine 9 Cytarabine 9 venetoclax 5 fludarabine phosphate 5 Cyclophosphamide 5 Busulfan 5 thymoglobulin 4 Tacrolimus 4 Sirolimus 4 Mycophenolic Acid 4 Methotrexate 4 Azacitidine 4 aldesleukin 3 Whole-Body Irradiation 3 Interleukin-2 3 Antilymphocyte Serum 3 asciminib 2 Thiotepa 2 Peripheral Blood Stem Cell Transplantation 2 Mitoxantrone 2 Idarubicin 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Etoposide 2 Dasatinib 2 Cyclosporine 2 Bone Marrow Transplantation 2 Blood Specimen Collection 2 Behavior Therapy 2 zileuton 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leukemia, Myeloid × Sensitivity and Specificity × Clear all

NCT01864902 2016-01-28

CART33

Chinese PLA General Hospital

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡